NIPH Clinical Trials Search

Efficacy of peripheral parenteral nutrition solution on outcomes in robotic pancreatoduodenectomy

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	The patients who require robotic pancreatoduodenectomy
Date of first enrollment	21/05/2026
Target sample size	56
Countries of recruitment
Study type	Interventional
Intervention(s)	For postoperative fluid therapy, peripheral parenteral nutrition solution will be used; 2200ml per a day from postoprative day 1. The dosage can be adjusted according to the amount of oral intake.

Outcome(s)

Primary Outcome

Body weight loss rate on postoperative 1 month compared t admission

Secondary Outcome

Muscle mass reduction rate before discharge Body composition changes before discharge Changes of skeletal muscle mass, weight loss rate, body composition on postoperative 1 month Nutrition-related blood index (TP, Alb, pre-Alb, T-Chol, lymphocyte count, CRP) Inflammatory reaction increased (postoperative maximum values of WBC and CRP) Postoperative outcomes (length of hospital stay, complications, etc) Postoperative liver and renal dysfunction (AST, ALT, T-Bil, BUN, Cr) Postoperative QOL evaluation (PGSAS-45) peripheral parenteral nutrition solution dosage during observation period

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	1.Age is 18 years or older 2.The patients who receive robotic pancreatoduodenectomy at our institution 3. Patients who have given written informed consent
Exclude criteria	1. patients who cannot give consent 2. severe respiratory dysfunction (arterial PaO2 <70 mmHg) 3. severe cardiac dysfunction (New York Heart Association 3 or more) 4. severe hepatic dysfunction (Child Pugh classification C) 5. severe renal dysfunction (hemodialysis) 6. acute bacterial infections 7. severe psychiatric disorder 8. patients with distant metastases 9. palliative surgery 10. emergency surgery 11. investigator not available